Open an account

Eledon Pharmaceuticals

ELDN · NASDAQ

$2.26+$0.095 (+4.40%)TodayMarket closed ·
Prev close $2.16

About ELDN

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company, which engages in development of therapies to protect transplanted organs and prevent rejection. The company is headquartered in Irvine, California and currently employs 33 full-time employees. The company went IPO on 2014-09-17. The firm is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular pathway. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. Tegoprubart is engineered to potentially both improve safety and provides pharmacokinetic, pharmacodynamic, and dosing advantages. CD40L is primarily expressed on activated CD4+ T cells, platelets, and endothelial cells while the CD40 receptor is constitutively expressed on antigen-presenting cells, such as macrophages and dendritic cells, as well as B cells.

Employees
33
Headquarters
Irvine, California
Listed
Sep 17, 2014
Sector
Health Care
Industry
Biotechnology
Website
eledon.com

ELDN key statistics

Market cap
183.24M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
875.44K
Volume
740.36K
Open price
$2.16
High today
$2.33
Low today
$2.14
52 Week high
$4.60
52 Week low
$1.35

Eledon Pharmaceuticals (ELDN) at a glance

Eledon Pharmaceuticals (ELDN) last traded at $2.26, with a market cap of 183.24M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $2.14 and $2.33. The current price is 5.4% above the day's low and 3.2% below its high.

Volume so far is 740.36K shares, in line with the average of 875.44K shares a day.

Over the past year Eledon Pharmaceuticals has ranged from $1.35 to $4.60, and now sits 28% of the way up that range.

Eledon Pharmaceuticals met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$0.27 per share against an estimate of -$0.1612.

The average analyst price target is $9.18, 307.1% above the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 2 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 7 analystsAvg $9.18
Low
$7.07
Now
$2.26
High
$12.60

ELDN earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 82.5% on average.

  1. Q3 FY24: reported -$0.32 per share against an estimate of -$0.3213
  2. Q4 FY24: reported $0.67 per share against an estimate of -$0.3244
  3. Q1 FY25: reported -$0.08 per share against an estimate of -$0.3094
  4. Q2 FY25: reported -$0.13 per share against an estimate of -$0.2346
  5. Q3 FY25: reported -$0.21 per share against an estimate of -$0.255
  6. Q4 FY25: reported -$0.10 per share against an estimate of -$0.2074
  7. Q1 FY26: reported -$0.33 per share against an estimate of -$0.1862
  8. Q2 FY26: reported -$0.27 per share against an estimate of -$0.1612

ELDN news

  • Press releasePRNewswire

    A Diabetes Therapy Just Locked In Its Cell Supplier, and the Race to End Insulin Injections Is Heating Up

  • Press releasePRNewswire

    The Longevity Protein Race Reaches Manufacturing: One Microcap Just Completed A GMP Master Cell Bank For Its Anti-Aging Klotho Therapy

  • NewcelX Completes Type B Pre-IND Meeting With FDA; Administration Provided Constructive Feedback And Alignment On Proposed Strategy

  • Press releaseGlobe Newswire

    NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes

  • Press releaseBusiness Wire

    Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial

  • Press releaseGlobe Newswire

    Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress

  • Press releasePRNewswire

    Why Smart Money Is Shifting From Clinical Data to Manufacturing Lines

  • Newcelx Announces Collaborative Research Agreement With Eledon Pharmaceuticals To Advance The NCEL-101 Program For Type 1 Diabetes

Similar companies

Companies in the same industry as Eledon Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.